Zymeworks Inc Says Termination Agreement Does Not Terminate The Zanidatamab License And Collaboration Agreement
Portfolio Pulse from Benzinga Newsdesk
Zymeworks Inc has announced that the termination agreement does not end the Zanidatamab License and Collaboration Agreement.
September 21, 2023 | 8:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zymeworks Inc's termination agreement does not terminate the Zanidatamab License and Collaboration Agreement, which could be seen as a positive sign by investors.
The news that the termination agreement does not end the Zanidatamab License and Collaboration Agreement could be seen as a positive sign by investors. This could potentially lead to a short-term increase in the stock price of Zymeworks Inc.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100